Supplemental Digital Content 5

Table. Patient Disposition (ITT Population)

Patients, n (%)	Brimo DDS 132 µg (n=49)	Brimo DDS 264 µg (n=41)	Sham (n=23)
Completed month 6	44 (89.8)	36 (87.8)	22 (95.7)
Completed month 12	40 (81.6)	34 (82.9)	22 (95.7)
Completed month 24	37 (75.5)	31 (75.6)	21 (91.3)
Reason for discontinuation			
Adverse event*	6 (12.2)	5 (12.2)	1 (4.3)
Withdrew consent	2 (4.1)	1 (2.4)	1 (4.3)
Personal reason	1 (2.0)	2 (4.9)	0 (0.0)
Lost to follow-up	2 (4.1)	1 (2.4)	0 (0.0)
Protocol violation†	1 (2.0)	1 (2.4)	0 (0.0)

Brimo DDS, brimonidine drug delivery system; ITT, intent-to-treat.

*None of the adverse events leading to patient discontinuation from the study were considered to be related to the study treatment.

†Two enrolled patients (1 randomized to Brimo DDS 132 µg and 1 randomized to Brimo DDS 264 µg) were determined to be ineligible at the baseline visit and were discontinued from the study for the protocol violation without receiving study treatment; these patients were excluded from the per-protocol and safety populations.